Shares in telehealth company Hims & Hers Health (HIMS) flowed higher today as it bought blood sampling business YourBio Health.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Samples in Seconds
YourBio develops technologies designed to simplify the process of taking blood from nervous and often pale-faced patients.
Its TAP device uses bladeless microneedles thinner than an eyelash to produce high-quality capillary blood samples in seconds, without the pain or complexity of traditional methods, like fingerstick -pricking a fingertip- or venipuncture which is when a needle is used to take blood from a vein.
Not only is it less painful for patients, the technology also means that blood samples can be taken outside of traditional clinic settings like a doctor’s office or hospital. That could mean in the comfort of a patient’s home.
“The next generation of health innovation will be built on proprietary technologies that make wellness simpler, more comfortable, and more human,” said Andrew Dudum, founder and CEO of Hims & Hers. “YourBio’s patented TAP and HALO technologies represent major advancements in user experience and design.”
Dr. Michael Mina, Chief Scientific Officer at YourBio Health, added: “This technology has the potential to change how people engage with routine blood collection – replacing long waits and painful needles with a far more convenient, user-friendly experience.”
Fuels Innovation Engine
HIMS said that the transaction is expected to close in early 2026 and will be funded entirely with cash from the balance sheet. However, it did not reveal how much it was paying for YourBio.
HIMS will hope the deal which “fuels its in-house innovation engine” and boosts its technology offering will give much needed first-aid to its ailing share price.
It has slumped 33% over the last six months as investors worry about its dependence on GLP-1 weight loss drugs, the price reductions of those treatments, as well as a downturn in company app downloads and web traffic.
But this and other recent deals show that it is determined to get back into shape. It bought at-home blood-testing facility, Trybe Labs, in February for $5.1 million. It’s being used to onboard patients in Hims’ new hormone treatment segments.
It also bought European telehealth company Zava in July for $265.7 million. It has 1.3 million active customers.
Is HIMS a Good Stock to Buy Now?
On TipRanks, HIMS has a Hold consensus based on 2 Buy, 6 Hold and 3 Sell ratings. Its highest price target is $85. HIMS stock’s consensus price target is $46.25, implying a 20.44% upside.
